SUPERA® Stent Approved for Private Reimbursement in Australia
2 pages
English

SUPERA® Stent Approved for Private Reimbursement in Australia

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
2 pages
English
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

Description

SUPERA® Stent Approved for Private Reimbursement in Australia PR Newswire WEBSTER, Texas, Sept. 28, 2012 - IDEV Technologies Continues Expansion in Asia Pacific Region WEBSTER, Texas, Sept. 28, 2012 /PRNewswire/ -- IDEV Technologies, Inc.

Informations

Publié par
Nombre de lectures 13
Langue English

Extrait

SUPERA® Stent Approved for Private Reimbursement in Australia
PR Newswire WEBSTER, Texas, Sept. 28, 2012
- IDEV Technologies Continues Expansion in Asia Pacific Region WEBSTER, Texas,Sept. 28, 2012/PRNewswire/ -- IDEV Technologies, Inc. (IDEV), an emerging global innovator in peripheral devices, today announced that Private Healthcare Australia has granted the Company a reimbursement code for the SUPERA® stent.TheAugust 2012Prostheses List was effective August 30This is an important milestone as the Company continues to, 2012. build a solid foundation in theAsia Pacificregion. "Gaining the private reimbursement code opens a significant portion of the Australian market to this exciting technology," commented Trent Reutiman, IDEV's Vice President of Global Commercial Operations."Working closely with our distributor inAustraliaandNew Zealand, Device Technologies, we will be able to move quickly to provide the SUPERA stent to physicians who have been awaiting reimbursement." "This is critically important as we implement our long term strategy in theAsia Pacificregion, one of the fastest growing global markets. We are pleased that Private Healthcare Australia has recognized the benefits of our technology by granting the reimbursement codes," said Christopher Owens, President and CEO of IDEV. In the past eighteen months the Company has initiated sales, marketing, and regulatory activities in multiple countries in the region, including the initiation of product registrations inJapanandChina, as well as increased sales activities in Hong Kongand countries of the ASEAN (Association of South-East Asian Nations) region. The SUPERA stent was designed and engineered to mimic the structure and function of vascular anatomy.Clinical evidence demonstrates that SUPERA is the most fracture resistant stent available, with excellent outcomes even in challenging anatomical areas. About IDEV Technologies, Incorporated IDEV Technologies, Inc. (IDEV) is a developer of endovascular technologies designed to protect and restore anatomical function. IDEV's worldwide headquarters is located inWebster, Texasand its European headquarters is located in Beuningen,The Netherlands. The SUPERA stent is currently indicated inthe United Statesfor the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA). For more information please visit www.idevmd.com or www.device.com.au. About Private Healthcare Australia Limited Private Healthcare Australia Limited, formerly known as the Australian Health Insurance Association is the Australian private health industry's peak representative body that represents 23 health funds throughoutAustraliaand collectivel coversover 95% of therivate health insurance industr.
Private Healthcare Australia member funds today provide healthcare benefits for approximately 12 million Australians. For more information please visit http://www.privatehealthcareaustralia.org.au. Contact:Donna Lucchesi Vice President, Global Marketing IDEV Technologies, Incorporated +1 (281) 525-2000
  • Univers Univers
  • Ebooks Ebooks
  • Livres audio Livres audio
  • Presse Presse
  • Podcasts Podcasts
  • BD BD
  • Documents Documents